tiprankstipranks
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
US Market
TRDA
Entrada Therapeutics Inc
RESEARCH TOOLSreports
Want to see TRDA full AI Analyst Report?

Entrada Therapeutics Inc (TRDA) Stock Forecast & Price Target

159 Followers
See the Price Targets and Ratings of:

TRDA Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Entrada
Therapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TRDA Stock 12 Month Forecast

Average Price Target

$19.50
▲(39.39% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Entrada Therapeutics Inc in the last 3 months. The average price target is $19.50 with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 39.39% change from the last price of $13.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.5,15.307692307692308,16.115384615384617,16.923076923076923,17.73076923076923,18.53846153846154,19.346153846153847,20.153846153846153,20.96153846153846,21.76923076923077,22.576923076923077,23.384615384615387,24.192307692307693,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.5,14.884615384615385,15.26923076923077,15.653846153846153,16.03846153846154,16.423076923076923,16.807692307692307,17.192307692307693,17.576923076923077,17.96153846153846,18.346153846153847,18.73076923076923,19.115384615384617,{"y":19.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.5,14.153846153846153,13.807692307692308,13.461538461538462,13.115384615384615,12.76923076923077,12.423076923076923,12.076923076923077,11.73076923076923,11.384615384615385,11.038461538461538,10.692307692307693,10.346153846153847,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$19.50Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Roth MKM Analyst forecast on TRDA
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$10
Buy
-28.52%
Downside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Entrada Therapeutics Inc (NASDAQ: TRDA) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
H.C. Wainwright Analyst forecast on TRDA
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
05/08/26
Entrada Therapeutics downgraded to Neutral from Buy at H.C. WainwrightEntrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
William Blair Analyst forecast on TRDA
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Beam Therapeutics (NASDAQ: BEAM)
TD Cowen Analyst forecast on TRDA
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
Evercore ISI Analyst forecast on TRDA
Jonathan Miller
Evercore ISI
Evercore ISI
$25
Buy
78.70%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Entrada Therapeutics Inc (NASDAQ: TRDA), Edgewise Therapeutics (NASDAQ: EWTX) and Elevance Health (NYSE: ELV)
Guggenheim Analyst forecast on TRDA
Debjit Chattopadhyay
Guggenheim
Guggenheim
$20
Buy
42.96%
Upside
Reiterated
04/23/26
Guggenheim Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Oppenheimer Analyst forecast on TRDA
Kostas Biliouris
Oppenheimer
Oppenheimer
$21→$23
Buy
64.40%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Viridian Therapeutics (NASDAQ: VRDN)
Cantor Fitzgerald Analyst forecast on TRDA
Yanni Souroutzidis
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
04/01/26
Entrada Therapeutics initiated with an Overweight at Cantor FitzgeraldEntrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Roth MKM Analyst forecast on TRDA
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$10
Buy
-28.52%
Downside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Entrada Therapeutics Inc (NASDAQ: TRDA) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
H.C. Wainwright Analyst forecast on TRDA
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
05/08/26
Entrada Therapeutics downgraded to Neutral from Buy at H.C. WainwrightEntrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
William Blair Analyst forecast on TRDA
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Beam Therapeutics (NASDAQ: BEAM)
TD Cowen Analyst forecast on TRDA
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
Evercore ISI Analyst forecast on TRDA
Jonathan Miller
Evercore ISI
Evercore ISI
$25
Buy
78.70%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Entrada Therapeutics Inc (NASDAQ: TRDA), Edgewise Therapeutics (NASDAQ: EWTX) and Elevance Health (NYSE: ELV)
Guggenheim Analyst forecast on TRDA
Debjit Chattopadhyay
Guggenheim
Guggenheim
$20
Buy
42.96%
Upside
Reiterated
04/23/26
Guggenheim Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Oppenheimer Analyst forecast on TRDA
Kostas Biliouris
Oppenheimer
Oppenheimer
$21→$23
Buy
64.40%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Viridian Therapeutics (NASDAQ: VRDN)
Cantor Fitzgerald Analyst forecast on TRDA
Yanni Souroutzidis
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
04/01/26
Entrada Therapeutics initiated with an Overweight at Cantor FitzgeraldEntrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Entrada Therapeutics Inc

3 Months
Boobalan PachaiyappanRoth MKM
Success Rate
6/13 ratings generated profit
46%
Average Return
+0.93%
Copying Boobalan Pachaiyappan's trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of +0.93% per trade.
1 Year
Boobalan PachaiyappanRoth MKM
Success Rate
5/13 ratings generated profit
38%
Average Return
-5.87%
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -5.87% per trade.
2 Years
Boobalan PachaiyappanRoth MKM
Success Rate
2/13 ratings generated profit
15%
Average Return
-32.38%
Copying Boobalan Pachaiyappan's trades and holding each position for 2 Years would result in 15.38% of your transactions generating a profit, with an average return of -32.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRDA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
4
8
9
9
4
Buy
3
6
8
8
6
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
14
17
17
11
In the current month, TRDA has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TRDA average Analyst price target in the past 3 months is 19.50.
Each month's total comprises the sum of three months' worth of ratings.

TRDA Financial Forecast

TRDA Earnings Forecast

Next quarter’s earnings estimate for TRDA is -$1.06 with a range of -$1.34 to -$0.68. The previous quarter’s EPS was -$0.95. TRDA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TRDA has Performed in-line its overall industry.
Next quarter’s earnings estimate for TRDA is -$1.06 with a range of -$1.34 to -$0.68. The previous quarter’s EPS was -$0.95. TRDA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TRDA has Performed in-line its overall industry.

TRDA Sales Forecast

Next quarter’s sales forecast for TRDA is $2.23M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $875.00K. TRDA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TRDA has Performed in-line its overall industry.
Next quarter’s sales forecast for TRDA is $2.23M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $875.00K. TRDA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TRDA has Performed in-line its overall industry.

TRDA Stock Forecast FAQ

What is TRDA’s average 12-month price target, according to analysts?
Based on analyst ratings, Entrada Therapeutics Inc’s 12-month average price target is 19.50.
    What is TRDA’s upside potential, based on the analysts’ average price target?
    Entrada Therapeutics Inc has 39.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TRDA a Buy, Sell or Hold?
          Entrada Therapeutics Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Entrada Therapeutics Inc’s price target?
            The average price target for Entrada Therapeutics Inc is 19.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $10.00. The average price target represents 39.39% Increase from the current price of $13.99.
              What do analysts say about Entrada Therapeutics Inc?
              Entrada Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of TRDA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.